WRAL Tech Wire

RTP-based biotech firm Chimerix expands management team

Chimerix

On The Web

• Chimerix

Site Search

Chimerix, a biotechnology firm that is developing antiviral therapeutics that can be delivered orally, is expanding its management team by adding a chief operating post.

Filling the job is Kenneth Moch, an industry veteran with more than two decades of experience in biomedical finance and management.

Moch will report to Chief Executive Officer George Painter.

"With a rich pipeline of next-generation antiviral drug candidates, productive platform technology, an extraordinary library of new leads and supportive top-tier investors, Chimerix combines deep assets with the scientific heritage necessary to emerge at the forefront of antiviral drug development," Moch said in a statement. "I am excited to join this veteran team. We have the opportunity to create much-needed new pharmaceutical products with promise in a broad range of challenging viral diseases."

Moch most recently worked with Euclidean Life Science Advisors, a consulting firm that he founded. He also has worked as CEO of BioMedical Enterprises, managing director of healthcare investment banking at ThinkEquity Partners, and as CEO at biotech firm Alteon.

A graduate of Princeton University with a degree in biochemistry, he earned an MBA at Stanford.

Chimerix was launched in 2002. It utilizes proprietary drug development technology developed at the University of California at San Diego and the Veterans Administration Hospital in San Diego, CA.

Painter, a former executive with Triangle Pharmaceuticals and Glaxo Wellcome, was among the early pioneers in efforts to develop drugs to combat HIV. Triangle developed the drug Coviracil before being acquired by Gilead Sciences in 2003.

Biotech & Life Science

The latest biotechnology and life science news. Read more articles…